Research report and Initiation of coverage by Euroz, page-26

We are due news on Ph2 Canafliglozin Janssen study & also Endometriosis. Would also be nice to get an update on how COVID-19 tests (2) are progressing.

I agree in regards to other SGLT2 inhibitors. Different drugs but very similar. AstraZeneca who makes Farxiga/Forxiga has a collaboration with RenalytixAI.

Be nice if J&J licenced PromarkerD as a CDx for canafliglozin & I think this was the intention all along. I can’t see why it wouldn’t work for other SGLT2 class, but maybe validation required in trials with individual drugs (not like the last 2 years or so validating the actual PD test).

Just waiting on that data now. The amount of studies on Canafliglozin is phenomenal.

Recent CREDENCE post hoc analysis has shown that patients remaining on Canafliglozin with eGFR <30mmol/L have shown benefit & slowed progression.

(if you can’t read the whole article, please let me know as have a log in & copy & paste).

https://www.medscape.com/viewarticle/94204

There is also a lengthy study due for completion June 2021 on safety & efficacy of Canafliglozin in children:

https://www.mountsinai.org/clinical-trials/study-to-investigate-efficacy-safety-of-canagliflozin-in-children-adolescents-10-to-18-years-with-type-2-diabetes-mellitus



GLTAH